Tag: Lu-177 PNT2002
-
Lu-177 PNT2002 Combined with SBRT Delays Prostate Cancer Progression
Overview New data presented at the American Society for Radiation Oncology (ASTRO) meeting suggest that adding the radiopharmaceutical Lu-177 PNT2002 to stereotactic body radiation therapy (SBRT) can significantly delay disease progression in men with oligometastatic, or limited, prostate cancer. The LUNAR trial compared SBRT alone to a two-cycle course of Lu-177 PNT2002 followed by SBRT,…
-
Lu-177 PNT2002 Added to SBRT Delays Prostate Cancer Progression
New approach combines Lu-177 PNT2002 with SBRT In a pioneering study presented at the American Society for Radiation Oncology (ASTRO) meeting, researchers explored whether adding lutetium-177 (Lu-177) PNT2002 to stereotactic body radiation therapy (SBRT) could improve outcomes for men with oligometastatic, or limited, prostate cancer. The strategy targets occult micrometastases that often drive progression after…